Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events
…, S Snapinn, KE Harris, P Aurup, JM Edelman… - Jama, 2004 - jamanetwork.com
ContextElectrocardiographic left ventricular hypertrophy (LVH) is a strong predictor of
cardiovascular (CV) morbidity and mortality. However, the predictive value of changes in the …
cardiovascular (CV) morbidity and mortality. However, the predictive value of changes in the …
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) …
…, J Rokkedal, KE Harris, JM Edelman… - Circulation, 2004 - Am Heart Assoc
Background— An echocardiographic substudy of the Losartan Intervention for Endpoint
Reduction in Hypertension (LIFE) trial was designed to test the ability of losartan to reduce left …
Reduction in Hypertension (LIFE) trial was designed to test the ability of losartan to reduce left …
Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial
…, JM Stocks, BC Stoel, L Huang, Z Yao, JM Edelman… - The Lancet, 2015 - thelancet.com
Background The efficacy of α1 proteinase inhibitor (A1PI) augmentation treatment for α1
antitrypsin deficiency has not been substantiated by a randomised, placebo-controlled trial. CT-…
antitrypsin deficiency has not been substantiated by a randomised, placebo-controlled trial. CT-…
Influence of body mass index on the response to asthma controller agents
…, CM Hustad, E Grant, JM Edelman - European …, 2006 - Eur Respiratory Soc
The incidence of asthma has been positively associated with obesity. Asthma comprises
diverse “phenotypes” reflecting heterogeneity in a number of characteristics, including response …
diverse “phenotypes” reflecting heterogeneity in a number of characteristics, including response …
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
…, S Oparil, H Wedel, P Aurup, JM Edelman… - Journal of …, 2002 - journals.lww.com
… Edelman are researchers at Merck who have contributed to the work on diabetes. All
other authors were members of the LIFE steering committee and have commented on the …
other authors were members of the LIFE steering committee and have commented on the …
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension
…, S Julius, LH Lindholm, MS Nieminen, JM Edelman… - Jama, 2006 - jamanetwork.com
… Dr Edelman is employed by Merck & Co and reported owning stock in the company. Ms Hille
is employed by Merck & Co and reported owning stock in the company. Dr Dahlöf reported …
is employed by Merck & Co and reported owning stock in the company. Dr Dahlöf reported …
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention For Endpoint reduction in Hypertension (LIFE) …
…, S Snapinn, KE Harris, P Aurup, JM Edelman… - Circulation, 2003 - Am Heart Assoc
Background— Electrocardiographic left ventricular hypertrophy (LVH) predicts cardiovascular
morbidity and mortality, and regression of ECG LVH may predict improved prognosis in …
morbidity and mortality, and regression of ECG LVH may predict improved prognosis in …
Twenty-year follow-up of patients with permanently bonded mandibular canine-to-canine retainers
FA Booth, JM Edelman, WR Proffit - American Journal of Orthodontics and …, 2008 - Elsevier
Introduction: Many orthodontists believe permanent retention is the only way to maintain ideal
tooth alignment after treatment. Fixed bonded retainers are now routinely left in place for …
tooth alignment after treatment. Fixed bonded retainers are now routinely left in place for …
Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction: a randomized, double-blind trial
JM Edelman, JA Turpin, EA Bronsky… - Annals of internal …, 2000 - acpjournals.org
… Critical revision of the article for important intellectual content: JM Edelman, EA Bronsky, J.
Grossman, AF Ghannam, PT DeLucca, GJ Gormley, DS … Obtaining of funding: JM Edelman. …
Grossman, AF Ghannam, PT DeLucca, GJ Gormley, DS … Obtaining of funding: JM Edelman. …
Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID …
…, MA Tortorici, M Fries, JM Edelman… - The Lancet …, 2017 - thelancet.com
Background Purified α1 proteinase inhibitor (A1PI) slowed emphysema progression in patients
with severe α1 antitrypsin deficiency in a randomised controlled trial (RAPID-RCT), which …
with severe α1 antitrypsin deficiency in a randomised controlled trial (RAPID-RCT), which …